Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have earned an average recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.3333.

Several research firms recently issued reports on UNCY. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Monday, December 29th. Westpark Capital initiated coverage on Unicycive Therapeutics in a report on Thursday, February 19th. They issued a “buy” rating for the company. Finally, Guggenheim restated a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th.

Institutional Trading of Unicycive Therapeutics

A number of institutional investors have recently made changes to their positions in UNCY. Vivo Capital LLC raised its holdings in shares of Unicycive Therapeutics by 57.4% during the third quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock valued at $7,804,000 after purchasing an additional 652,901 shares during the last quarter. Millennium Management LLC purchased a new stake in Unicycive Therapeutics during the 4th quarter valued at $5,856,000. Vanguard Group Inc. lifted its holdings in shares of Unicycive Therapeutics by 8.7% during the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock valued at $2,873,000 after buying an additional 52,925 shares during the period. Cantor Fitzgerald L. P. bought a new position in shares of Unicycive Therapeutics during the 4th quarter valued at $1,154,000. Finally, Geode Capital Management LLC boosted its stake in shares of Unicycive Therapeutics by 36.2% in the 4th quarter. Geode Capital Management LLC now owns 171,290 shares of the company’s stock worth $989,000 after buying an additional 45,563 shares during the last quarter. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Stock Performance

Shares of Unicycive Therapeutics stock opened at $6.73 on Monday. The company has a 50-day simple moving average of $6.63 and a two-hundred day simple moving average of $5.64. The stock has a market capitalization of $144.63 million, a PE ratio of -1.70 and a beta of 1.82. Unicycive Therapeutics has a 52-week low of $3.71 and a 52-week high of $11.00.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.